Casdin Capital 13F holdings, Q1 2017
Holdings as of March 31, 2017 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 29 US equity positions worth $169.5m in its Q1 2017 13F filing. The largest position was SG7 at 10.7% of the reported book, followed by FOUNDATION MEDICINE INC and LOXO ONCOLOGY INC. Against the Q4 2016 filing, it opened 9 new positions, added to 8 and reduced 9 among the top 29 holdings.
What did Casdin Capital own in Q1 2017? Top 29 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2016 |
|---|---|---|---|---|---|---|---|
| 1 | SG7 SAGE THERAPEUTICS INC | 10.7% | $18.1m | 255,000 | -2% | reduced | |
| 2 | FOUNDATION MEDICINE INC | 9.1% | $15.5m | 480,000 | -12% | reduced | |
| 3 | LOXO ONCOLOGY INC | 8.9% | $15.1m | 360,000 | 0% | held | |
| 4 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 8.2% | $13.9m | 237,500 | -1% | reduced |
| 5 | 2655787D BLUEPRINT MEDICINES CORP | 6.9% | $11.8m | 294,500 | 20% | added | |
| 6 | EVH EVOLENT HEALTH INC | Healthcare | 6.8% | $11.6m | 520,000 | -6% | reduced |
| 7 | EPIZYME INC | 4.9% | $8.3m | 485,000 | 76% | added | |
| 8 | SPARK THERAPEUTICS INC | 4.2% | $7.2m | 135,000 | 5% | added | |
| 9 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 3.9% | $6.6m | 500,000 | 30% | added |
| 10 | GNMK GENMARK DIAGNOSTICS INC | 3.0% | $5.1m | 400,000 | -22% | reduced | |
| 11 | AUDENTES THERAPEUTICS INC | 2.6% | $4.4m | 260,000 | – | new | |
| 12 | SGMOQ SANGAMO THERAPEUTICS INC | Healthcare | 2.6% | $4.4m | 850,000 | – | new |
| 13 | MDRX ALLSCRIPTS HEALTHCARE SOLUTN | Healthcare | 2.3% | $3.9m | 310,000 | 11% | added |
| 14 | GLOBAL BLOOD THERAPEUTICS IN | 2.2% | $3.7m | 101,500 | -67% | reduced | |
| 15 | PACB PACIFIC BIOSCIENCES CALIF IN | Healthcare | 2.1% | $3.6m | 700,000 | – | new |
| 16 | MYOKARDIA INC | 2.1% | $3.5m | 265,000 | 0% | held | |
| 17 | KITE PHARMA INC | 2.0% | $3.3m | 42,500 | -55% | reduced | |
| 18 | CDXS CODEXIS INC | Healthcare | 1.9% | $3.2m | 675,000 | – | new |
| 19 | AMYRIS INC | 1.9% | $3.2m | 6,000,000 | 75% | added | |
| 20 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 1.8% | $3.1m | 177,500 | 39% | added |
| 21 | EDIT EDITAS MEDICINE INC | Healthcare | 1.8% | $3.0m | 133,333 | 105% | added |
| 22 | SYROS PHARMACEUTICALS INC | 1.7% | $2.9m | 182,141 | 0% | held | |
| 23 | JOUNCE THERAPEUTICS INC | 1.7% | $2.9m | 130,000 | – | new | |
| 24 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 1.7% | $2.8m | 55,000 | -35% | reduced |
| 25 | T8S TESARO INC | 1.6% | $2.7m | 17,500 | – | new | |
| 26 | BLUEBIRD BIO INC | 1.4% | $2.3m | 25,500 | -69% | reduced | |
| 27 | CLOVIS ONCOLOGY INC | 0.9% | $1.5m | 23,000 | – | new | |
| 28 | ADVERUM BIOTECHNOLOGIES INC | 0.7% | $1.1m | 420,000 | – | new | |
| 29 | CRIS CURIS INC | 0.4% | $639.0k | 230,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.